The conservation guide for adult and pediatric IV push medications is intended to help mitigate Hurricane Helene’s impact on supply from Baxter International, Inc. North Cove facility in Marion, N.C.
A Vizient, Inc. expert will moderate a panel discussion at the 2024 Compounding Quality Center of Excellence Annual Conference, hosted by the Food and Drug Administration from August 21-23.
The report points to expanding indications of previously approved medications, such as semaglutide, as partial cause for the projected increase. It also urges providers to prepare for an increased number of high-cost cell and gene therapies entering the ma...
The inaugural symposium brought together leading healthcare providers, payers and manufacturers of high-cost, ultra-specialty pharmaceuticals to discuss the promise the rapidly expanding market of cell, gene and other advanced therapies.
Vizient, Inc. submitted comments to the Food and Drug Administration on the development of a program aimed at promoting drug manufacturers’ quality management maturity.
A Vizient white paper demonstrates how the lack of information about medication access across the supply chain is exacerbating the shortage of seven oncology drugs used to treat a multitude of cancers.
Vizient, Inc. announced today that Steven Lucio, PharmD, BCPS, senior principal, pharmacy solutions for Vizient, will share insights on biosimilars in the panel discussion, "Building the Sustainable Future of Biosimilars".
Vizient, Inc. released its Winter 2023 Pharmacy Market Outlook, forecasting a 3.78% overall drug price inflation rate for the calendar year beginning, July 1, 2023.
This week, Vizient, Inc. offered support for the Biologics Competition Act of 2022, H.R. 8877. This important bipartisan legislation would strengthen the healthcare market by minimizing barriers to the substitution of interchangeable biological products an...
Vizient, Inc. pharmacy experts, including Pharmacy Executive Director Carolyn Liptak and Pharmacy Contracting Director April Yoo, will present at the Food and Drug Administration's (FDA)
The survey of hospital leaders and pharmacy professionals from Vizient member hospitals across the country found that biosimilars are gaining inclusion in hospital formularies, something long seen as a necessity for greater adoption.
Vizient, Inc. released its Summer 2022 Pharmacy Market Outlook forecasting a 3.26% overall drug price inflation rate for the calendar year beginning Jan. 1, 2023. The rate reflects a continued trend toward moderation of the overall increase in drug prices,...
The finding is reported in the Vizient Winter 2022 Pharmacy Market Outlook, which forecasts an overall 3.09% increase in drug prices for July 1, 2022 through June 30, 2023.
The number of active drug shortages in the U.S. has remained above 200 since 2017. As a result, patients and prescribers in the U.S. face disruption in accessing medications, sometimes impacting life-saving care. The End Drug Shortages Alliance will provid...
While the report, an analysis of Vizient member pharmaceutical purchase data, forecasts that oncology will remain the top therapeutic class in spend by Vizient member purchases, it also projects COVID-19 to have a pronounced effect on member drug purchases...